pre-update Archives

On-Demand Webinar

eChalk Talk: How Oncology Drug Developers Can Prepare for FDA’s Project Optimus

Historically, the dosing strategy for oncology drugs has focused on use of the maximum tolerated…

CertaraMarch 22, 2022

Video

The Value of BaseCase

CertaraMarch 21, 2022

Announcement

Certara Selected by the European Medicines Agency to Provide Real World Solutions for Critical Regulatory Decisions

Princeton, N.J., March 17, 2022 -- Certara, Inc. today announced a four-year, framework service contract…

CertaraMarch 17, 2022

Press Coverage

The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics

We have often seen Dr. Hwi-yeol (Thomas) Yun, Associate Professor/Adjunct Professor at the College of…

CertaraFebruary 7, 2022

On-Demand Webinar

Improved Workflow and Expanded functionality of RsNLME v1.1

R Speaks NLME (RsNLME) is a collection of R packages and companion RShiny apps that…

CertaraJanuary 31, 2022

Blog

Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development

This blog will reflect on 3 things drug developers should pay attention to regarding safety…

CertaraJanuary 24, 2022

Press Coverage

Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies

Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and…

CertaraJanuary 19, 2022

Video

R Speaks NLME (RsNLME) Overview

This recording shows an overall review of RsNLME using Pirana and an extensive explanation on…

CertaraJanuary 19, 2022

White Paper

The Essential Components of Your Drug’s Biomarker Strategy

CertaraJanuary 14, 2022

On-Demand Webinar

What Oncology Drug Developers Should Expect from the FDA’s Project Optimus

Historically, the dosing strategy for oncology drugs has focused on the maximum tolerated dose. This…

CertaraJanuary 13, 2022

pre-update

eChalk Talk: How Oncology Drug Developers Can Prepare for FDA’s Project Optimus

The Value of BaseCase

Certara Selected by the European Medicines Agency to Provide Real World Solutions for Critical Regulatory Decisions

The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics

Improved Workflow and Expanded functionality of RsNLME v1.1

Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development

Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies

R Speaks NLME (RsNLME) Overview

The Essential Components of Your Drug’s Biomarker Strategy

What Oncology Drug Developers Should Expect from the FDA’s Project Optimus

Newsletter sign up

Quick links

Solutions

Contact